Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MYOV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.20
N/A
-0.75
vs -0.79
Q4.20
N/A
-0.82
vs -0.96
Q1.21
N/A
-0.89
vs -0.73
Q2.21
N/A
-0.67
vs -0.37
Q3.21
N/A
-0.23
vs -0.75
Q4.21
N/A
-0.68
vs -0.82
Q1.22
N/A
-0.63
vs -0.89
Q2.22
N/A
-0.22
vs -0.67
Q3.22
N/A
-0.47
vs -0.23
Q4.22
N/A
-0.59
vs -0.68
Sales Growth
YoY
Current
Estimates
Q3.20
NA
NA vs NA
Q4.20
NA
1.4M vs NA
Q1.21
NA
24.6M vs NA
Q2.21
+23%
41.1M vs 33.3M
Q3.21
NA
77.9M vs NA
Q4.21
+3848%
54.4M vs 1.4M
Q1.22
+134%
57.6M vs 24.6M
Q2.22
+184%
116.5M vs 41.1M
Q3.22
+35%
104.8M vs 77.9M
Q4.22
+84%
100.2M vs 54.4M
Return on Equity
QoQ
Q1.21
+23%
0.23
vs 0.27
Q2.21
+15%
0.15
vs 0.23
Q3.21
+6%
0.06
vs 0.15
Q4.21
+15%
0.15
vs 0.06
Q1.22
+13%
0.13
vs 0.15
Q2.22
+4%
0.04
vs 0.13
Q3.22
+9%
0.09
vs 0.04
Q4.22
+10%
0.1
vs 0.09
Institutionnal Ownership
QoQ
Q1.23
1
1
vs 127
-99%
Q2.23
1
1
vs 1
NA
Q3.23
1
1
vs 1
NA
Q4.23
1
1
vs 1
NA
Q1.24
1
1
vs 1
NA
Q2.24
1
1
vs 1
NA
Q3.24
1
1
vs 1
NA
Q4.24
1
1
vs 1
NA
Quote Panel
Key Metrics
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
NYSE
Unprofitable
Unprofitable
-0.01Â ( -0.04%)
Relative Strenght
97
Volume Buzz
107%
Earning Acce
No
Dist 52w H.
0%Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
SVB Leerink
upgradePrevious: Not converted
2022-08-09
Now: Outperform
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How MYOV compares to sector?
MYOV
-12x
